Drugs / OA-SYS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06485843 | May 2025 → Mar 2028 expected | osteoarthritis, knee | Ageless Biotech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OA-SYS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06485843 ↗ |
| Modality | Cell therapy | “Participants will receive the OA-SYS treatment, which includes adult stem cells, administered to the knee joint.” NCT06485843 ↗ |
| Route | Other | “adult stem cells, administered to the knee joint” NCT06485843 ↗ |